Jianmin Wang

Tianjin Cancer Hospital, Hexi, 300210, Tianjin, China
Author    Correspondence author
International Journal of Clinical Case Reports, 2024, Vol. 14, No. 4   
Received: 01 Jun., 2024    Accepted: 09 Jul., 2024    Published: 03 Aug., 2024

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The HOXB13 gene has emerged as a key factor in prostate cancer susceptibility, particularly its most notable variant, G84E, which is associated with a significantly increased risk of prostate cancer, especially in individuals with a family history or early-onset disease. This report explores the genetic mechanisms of HOXB13 variants, their role in regulating androgen receptor (AR) signaling, and their impact on prostate cancer aggressiveness and treatment resistance. The clinical applications of HOXB13 variants in early diagnosis, risk stratification, and personalized treatment strategies are also discussed. While HOXB13 shows great potential as a biomarker, challenges remain in translating these findings into widespread clinical applications, particularly in non-European populations. Future research must focus on large-scale population studies and the development of therapeutic strategies targeting HOXB13-driven pathways to enhance the management of prostate cancer.

HOXB13; Prostate cancer; Genetic variants; Androgen receptor signaling; Personalized treatment